Atlas Trials

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

Clinical trial NCT07558733 · RECRUITING

Trial details

NCT number
NCT07558733
Sponsor
Faeth Therapeutics
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
HR+ HER2- Breast Cancer
Start date
2026-04-22
Primary completion
2029-05-01
Enrollment
32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.